Predictive Technology Group, Inc. (PRED) announced the appointment of Michael Dey, Ph.D. to the Board of Directors of company. Dr. Dey will assist in corporate governance and guide the development and commercialization of technology and products in all PRED subsidiaries. In addition to serving as a PRED Board Member, Dr. Dey will continue as Chief Executive Officer of Predicitive Therapeutics, Inc. Before joining PRED, Dr. Dey had executive positions at Wyeth, later acquired by Pfizer, where he was both the President and the President of Scientific Affairs division for Wyeth’s Women’s Health Care business.